PSA vs RGEN · rev $1.23B vs P/E 143, rev $204.1M
PSA (PSA) versus Repligen Corporation (RGEN) — a side-by-side from cached financials, not a winner call.
PSA (PSA) common stock.
Repligen Corporation (RGEN) is a medical instruments & supplies company listed on NASDAQ.
Latest reported PSA revenue for 2026-06-30 was $1.23B. Net income was $500.0M. Revenue was up 1.2% from 2026-03-31 to 2026-06-30. PSA currently screens at market cap $0.
Latest reported RGEN revenue for 2026-06-30 was $204.1M. Net income was $5.0M. Revenue was up 5.1% from 2026-03-31 to 2026-06-30. RGEN currently screens at market cap $7.43B and trailing P/E 143.1.
PSA currently screens at market cap $0. RGEN currently screens at market cap $7.43B and trailing P/E 143.1.
Not investment advice. Open the PSA and RGEN stock pages for the full models.
Not investment advice.